Nanoparticle Albumin–Bound Paclitaxel for Metastatic Breast Cancer
- 1 November 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (31), 7768-7771
- https://doi.org/10.1200/jco.2005.08.002
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survivaJournal of Clinical Oncology, 2004
- Scheduling of Fluorouracil: A Forget-Me-Not in the Jungle of DoubletsJournal of Clinical Oncology, 2004
- Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast CancerJournal of Clinical Oncology, 2003
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-OverJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancerAnnals Of Oncology, 1994
- Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1993